Want to create an interactive transcript for this episode?
Podcast: Decera Clinical Education Infectious Disease Podcast
Episode: Investigational Dual PPAR Agonist, FXR Agonist With Fibrate, and Hyperlipidemia in People With PBC: Conference Coverage of AASLD
Description: During the 2023 American Association of the Study of Liver Diseases (AASLD) conference, exciting and important results from many primary biliary cholangitis (PBC) clinical trials were reported, including 3 late-breaking studies on the PPAR-delta agonist seladelpar, the dual PPAR agonist elafibranor, and the combination of the FXR agonist obeticholic acid and a fibrate.In this episode, Marlyn J. Mayo, MD, discusses topline results from several of these studies and more, including: A phase III study of an investigational dual PPAR α/δ agonist (elafibranor) in people with PBC who did not respond to or were intolerant of ursodeoxycholic acid (UDCA)A s...